Vanguard Group’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-1,521,404
| Closed | -$8.9M | – | 4241 |
|
|
2019
Q1 | $8.9M | Buy |
1,521,404
+905,682
| +147% | +$3.09M | ﹤0.01% | 2888 |
|
|
2018
Q4 | $801K | Sell |
615,722
-999,720
| -62% | -$1.74M | ﹤0.01% | 3628 |
|
|
2018
Q3 | $5.57M | Buy |
1,615,442
+11,006
| +0.7% | +$41.3K | ﹤0.01% | 3193 |
|
|
2018
Q2 | $7.3M | Buy |
1,604,436
+33,533
| +2% | +$134K | ﹤0.01% | 3051 |
|
|
2018
Q1 | $5.18M | Buy |
1,570,903
+218,300
| +16% | +$773K | ﹤0.01% | 3140 |
|
|
2017
Q4 | $5.28M | Buy |
1,352,603
+749,883
| +124% | +$4.08M | ﹤0.01% | 3115 |
|
|
2017
Q3 | $6.24M | Buy |
602,720
+77,721
| +15% | +$765K | ﹤0.01% | 3028 |
|
|
2017
Q2 | $5.12M | Buy |
524,999
+144,408
| +38% | +$1.01M | ﹤0.01% | 3071 |
|
|
2017
Q1 | $2.59M | Buy |
380,591
+61,729
| +19% | +$357K | ﹤0.01% | 3298 |
|
|
2016
Q4 | $1.75M | Sell |
318,862
-38,746
| -11% | -$274K | ﹤0.01% | 3401 |
|
|
2016
Q3 | $2.71M | Buy |
357,608
+22,675
| +7% | +$166K | ﹤0.01% | 3279 |
|
|
2016
Q2 | $2.73M | Buy |
334,933
+7,941
| +2% | +$99K | ﹤0.01% | 3246 |
|
|
2016
Q1 | $4.25M | Buy |
326,992
+4,664
| +1% | +$53.8K | ﹤0.01% | 3053 |
|
|
2015
Q4 | $6.47M | Buy |
322,328
+22,409
| +7% | +$386K | ﹤0.01% | 2866 |
|
|
2015
Q3 | $3.66M | Buy |
299,919
+38,766
| +15% | +$726K | ﹤0.01% | 3111 |
|
|
2015
Q2 | $5.39M | Buy |
261,153
+180,150
| +222% | +$4.26M | ﹤0.01% | 2985 |
|
|
2015
Q1 | $1.71M | Buy |
81,003
+20,823
| +35% | +$543K | ﹤0.01% | 3466 |
|
|
2014
Q4 | $1.85M | Buy |
60,180
+47,762
| +385% | +$1.33M | ﹤0.01% | 3313 |
|
|
2014
Q3 | $220K | Buy |
+12,418
| New | +$157K | ﹤0.01% | 3876 |
|
Vanguard Group's IMDZ Position: Q2 2019 in Review
Vanguard Group sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 1,521,404 shares — an estimated $8.9M sold.
Vanguard Group first reported a position in IMDZ in Q3 2014 and held it in 19 quarters. The position peaked at $8.9M in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Vanguard Group reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Vanguard Group sold 1,521,404 Immune Design Corp. shares in Q2 2019, an estimated $8.9M.
- Vanguard Group first reported a position in Immune Design Corp. in Q3 2014 and held it in 19 quarters.
- Vanguard Group's Immune Design Corp. position peaked at $8.9M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.